Ian S Reynolds1, Aobhlinn O'Toole2, Joseph Deasy1, Deborah A McNamara1, John P Burke3,4. 1. Department of Colorectal Surgery, Beaumont Hospital, Dublin 9, Ireland. 2. Department of Gastroenterology, Beaumont Hospital, Dublin 9, Ireland. 3. Department of Colorectal Surgery, Beaumont Hospital, Dublin 9, Ireland. johnburke@rcsi.ie. 4. Royal College of Surgeons, Dublin 2, Ireland. johnburke@rcsi.ie.
Abstract
PURPOSE: The current study aims to use meta-analytical techniques to compare the clinicopathological characteristics and survival outcomes of inflammatory bowel disease (IBD) associated and sporadic colorectal carcinoma (CRC). Patients with IBD have an established increased risk of developing CRC. There is no consensus, however, on the clinicopathological characteristics and survival outcomes of IBD associated CRC when compared to sporadic CRC. METHODS: A comprehensive search for published studies comparing IBD associated and sporadic CRC was performed. Random effect methods were used to combine data. This study adhered to the recommendations of the MOOSE guidelines. RESULTS: Data were retrieved from 20 studies describing 571,278 patients. IBD associated CRC had an increased rate of synchronous tumors (OR 4.403, 95% CI 2.320-8.359; p < 0.001), poor differentiation (OR 1.875, 95% CI 1.425-2.466; p < 0.001), and a reduced rate of rectal cancer (OR 0.827, 95% CI 0.735-0.930; p = 0.002). IBD associated CRC however did not affect the frequency of T3/T4 tumors (OR 0.931, 95% CI 0.782-1.108; p = 0.421), lymph node positivity (OR 1.061, 95% CI 0.929-1.213; p = 0.381), metastasis at presentation (OR 0.970, 95% CI 0.776-1.211; p = 0.786), sex distribution (OR 0.978, 95% CI 0.890-1.074; p = 0.640), or 5-year overall survival (OR 1.105, 95% CI 0.414-2.949; p = 0.842). CONCLUSIONS: In this large analysis of available data, IBD associated CRC was characterized by less rectal tumors and more synchronous and poorly differentiated tumors compared with sporadic cancers, but no discernable difference in sex distribution, stage at presentation, or survival could be identified.
PURPOSE: The current study aims to use meta-analytical techniques to compare the clinicopathological characteristics and survival outcomes of inflammatory bowel disease (IBD) associated and sporadic colorectal carcinoma (CRC). Patients with IBD have an established increased risk of developing CRC. There is no consensus, however, on the clinicopathological characteristics and survival outcomes of IBD associated CRC when compared to sporadic CRC. METHODS: A comprehensive search for published studies comparing IBD associated and sporadic CRC was performed. Random effect methods were used to combine data. This study adhered to the recommendations of the MOOSE guidelines. RESULTS: Data were retrieved from 20 studies describing 571,278 patients. IBD associated CRC had an increased rate of synchronous tumors (OR 4.403, 95% CI 2.320-8.359; p < 0.001), poor differentiation (OR 1.875, 95% CI 1.425-2.466; p < 0.001), and a reduced rate of rectal cancer (OR 0.827, 95% CI 0.735-0.930; p = 0.002). IBD associated CRC however did not affect the frequency of T3/T4 tumors (OR 0.931, 95% CI 0.782-1.108; p = 0.421), lymph node positivity (OR 1.061, 95% CI 0.929-1.213; p = 0.381), metastasis at presentation (OR 0.970, 95% CI 0.776-1.211; p = 0.786), sex distribution (OR 0.978, 95% CI 0.890-1.074; p = 0.640), or 5-year overall survival (OR 1.105, 95% CI 0.414-2.949; p = 0.842). CONCLUSIONS: In this large analysis of available data, IBD associated CRC was characterized by less rectal tumors and more synchronous and poorly differentiated tumors compared with sporadic cancers, but no discernable difference in sex distribution, stage at presentation, or survival could be identified.
Authors: Susan L Gearhart; Hari Nathan; Timothy M Pawlik; Elizabeth Wick; Jonathan Efron; Andrew D Shore Journal: Dis Colon Rectum Date: 2012-03 Impact factor: 4.585
Authors: Alexander C von Roon; George Reese; Julian Teare; Vasilis Constantinides; Ara W Darzi; Paris P Tekkis Journal: Dis Colon Rectum Date: 2007-06 Impact factor: 4.585
Authors: Megan M Garrity-Park; Edward V Loftus; Sandra C Bryant; William J Sandborn; Thomas C Smyrk Journal: Am J Gastroenterol Date: 2008-02 Impact factor: 10.864
Authors: N Harpaz; A L Peck; J Yin; I Fiel; M Hontanosas; T R Tong; J N Laurin; J M Abraham; B D Greenwald; S J Meltzer Journal: Hum Pathol Date: 1994-10 Impact factor: 3.466
Authors: Thierry Delaunoit; Paul J Limburg; Richard M Goldberg; James F Lymp; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2006-03 Impact factor: 11.382
Authors: Shahida Din; Kim Wong; Mike F Mueller; Anca Oniscu; James Hewinson; Catherine J Black; Martin L Miller; Alejandro Jiménez-Sánchez; Roy Rabbie; Mamunar Rashid; Jack Satsangi; David J Adams; Mark J Arends Journal: Clin Cancer Res Date: 2018-06-27 Impact factor: 12.531